Randomized trial · people

Abaloparatide: fewer new vertebral fractures vs placebo in ACTIVE

Checked against the paper Randomized trialPublished by PepVault

The takeaway

In a large phase 3 trial, abaloparatide cut new spine and nonvertebral fractures compared with placebo and caused high blood calcium less often than teriparatide.

Kind
Randomized trial
Studied in
People
Number studied
2463
Published
2016
Journal
JAMA

What they tested

The team tested whether daily abaloparatide prevents new vertebral (spine bone) fractures better than placebo in postmenopausal women at risk of osteoporotic fractures, and how safe it is.

How the study was done

A phase 3, double-blind, randomized trial at 28 sites in 10 countries in 2463 postmenopausal women with low bone density, mean age 69. For 18 months they took a daily shot under the skin of placebo (a dummy shot), abaloparatide in the 80 μg arm, or teriparatide in the 20 μg arm, which was open-label, meaning everyone knew they were getting it.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

PepVault for iPhone

Taking abaloparatide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

New vertebral fractures seen on X-ray were less common in both active drug groups than with placebo. The estimated rate of nonvertebral fractures was lower with abaloparatide than with placebo. Bone mineral density (BMD) at the total hip, femoral neck and lumbar spine rose more with abaloparatide than with placebo. Hypercalcemia (high blood calcium) occurred in 3.4% of women on abaloparatide vs 6.4% on teriparatide (risk difference −2.96, 95% CI −5.12 to −0.87).

What it doesn’t show

The study included only postmenopausal women and lasted 18 months, and 1901 of the 2463 women completed it. The main test compared abaloparatide with placebo; the teriparatide arm was not blinded, so this was not a full head-to-head efficacy test against other osteoporosis drugs.

The paper

Miller et al. Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial. JAMA. 2016.

The compound

More studies on Abaloparatide

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking abaloparatide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo